Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 72Specimen Handling 67Cyclophosphamide 57Cytarabine 51Biopsy 49fludarabine 42Azacitidine 37Rituximab 27fludarabine phosphate 21Magnetic Resonance Spectroscopy 21Vincristine 20Methotrexate 20blinatumomab 19Daunorubicin 19Prednisone 17ibrutinib 16Whole-Body Irradiation 16Injections 16Dexamethasone 16decitabine and cedazuridine drug combination 15Tacrolimus 14Mycophenolic Acid 14obinutuzumab 13Melphalan 13Granulocyte Colony-Stimulating Factor 13Doxorubicin 13Busulfan 13merphos 12acalabrutinib 12Stem Cell Transplantation 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
luspatercept × Other hematologic neoplasm × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡